Marksans Pharma

Marksans Pharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Marksans Pharma (MARKSANS.NS) as of Oct 21, 2026 is 5.49 B INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 4.63 B INR — a change of 18.79% (higher).

EBITDA

5.49 BINR

YoY

18.79%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Marksans Pharma is 2025 5.49 B INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Marksans Pharma was 2024 4.63 B INR. It decreases by 18.79% higher compared to the previous year.

The Marksans Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
783.99 M INR
Jan 1, 2019
1.32 B INR
Jan 1, 2020
1.92 B INR
Jan 1, 2021
3.40 B INR
Jan 1, 2022
2.59 B INR
Jan 1, 2023
3.50 B INR
Jan 1, 2024
4.63 B INR
Jan 1, 2025
5.49 B INR
The Marksans Pharma EBITDA history
YEAREBITDAYoY
5.49 BINR+18.79%
4.63 BINR+32.01%
3.50 BINR+35.34%
2.59 BINR-23.78%
3.40 BINR+76.64%
1.92 BINR+45.53%
1.32 BINR+68.54%
783.99 MINR+138.10%
329.26 MINR-75.13%
1.32 BINR-24.73%
1.76 BINR+54.33%
1.14 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Marksans Pharma Stock analysis

What does Marksans Pharma do? Marksans Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Marksans Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Marksans Pharma is 5.49 B INR in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Marksans Pharma changed from 4.63 B INR to 5.49 B INR, representing a 18.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Marksans Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Marksans Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Marksans Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Marksans Pharma